<DOC>
	<DOCNO>NCT00549770</DOCNO>
	<brief_summary>This study dose-ranging efficiacy study patient essential hypertension ass blood pressure lower effect , safety LCZ696 compare valsartan placebo . The study also evaluate efficacy safety AHU377 compare placebo .</brief_summary>
	<brief_title>Efficacy Safety LCZ696A Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Male female 18 include 75 year Patients mildtomoderate uncomplicated essential hypertension , untreated currently take antihypertensive therapy ( monotherapy combination therapy 2 drug ; therapy fix dose combination two active substance represent 2 drug ) Untreated patient must office msDBP≥ 95 mmHg randomization visit ( Visit 3 ) 2 precede visit ( Visits 1 2 ) . Treated patient must office msDBP≥ 90 mmHG washout ( Visit 2 ) , msDBP &gt; 95 mmHg baseline ( Visit 3 ) ; Severe hypertension ( msSBP ≥180 mmHg and/or msDBP ≥110 mmHg ) History angioedema , drugrelated otherwise , report patient Type 1 Type 2 diabetes mellitus ( accord ADA criterion ) History evidence secondary form hypertension , renal parenchymal hypertension , renovascular hypertension , coarctation aorta , primary hyperaldosteronism , Cushing 's disease , druginduced hypertension , unilateral bilateral renal artery stenosis , pheochromocytoma , polycystic kidney disease , etc . History angina pectoris , myocardial infarction , coronary bypass surgery , ischemic heart disease , surgical percutaneous arterial intervention kind ( coronary , carotid peripheral intervention ) , stroke , TIA ( transient ischemic attack ) , carotid artery stenosis , aortic aneurysm peripheral arterial disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hypertension , valsartan , LCZ696</keyword>
</DOC>